My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

25.86 -0.85 (-3.18%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 Next >

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected ↗

August 06, 2025

Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings.

Via Chartmill

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

July 25, 2025

Via Benzinga

Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis ↗

June 06, 2025

Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema.

Via Benzinga

Analyst Expectations For Arcutis Biotherapeutics's Future ↗

May 23, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts ↗

February 26, 2025

Via Benzinga

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

4 Analysts Have This To Say About Arcutis Biotherapeutics ↗

February 10, 2025

Via Benzinga

Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews ↗

January 13, 2025

Via Benzinga

Would Mark Minervini consider ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) a top stock pick? ↗

April 24, 2025

A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing?

Via Chartmill

Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews ↗

April 03, 2025

Via Benzinga

Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move ↗

March 25, 2025

A discussion whether the rebound could sustain, the worst scenario and the potential target price for the S&P 500.

Via Talk Markets

Topics Stocks Stocks / Equities

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 25, 2025

Via Benzinga

How does ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) stack up against Mark Minervini’s strategy? ↗

March 25, 2025

A fundamental and technical analysis of (NASDAQ:ARQT): Why ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) is Poised for High Growth.

Via Chartmill

Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts ↗

August 28, 2024

Via Benzinga

Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights ↗

July 30, 2024

Via Benzinga

Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? ↗

March 23, 2025

Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your...

Via Benzinga

What's Going On With Arcutis Biotherapeutics Stock Monday? ↗

March 17, 2025

Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis.

Via Benzinga

Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally ↗

February 26, 2025

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

Via Stocktwits

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗

February 06, 2025

The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.

Via Investor's Business Daily

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗

January 13, 2025

Via Benzinga

This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday ↗

December 30, 2024

Via Benzinga

This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 30, 2024

Via Benzinga

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 ↗

October 22, 2024

Via Benzinga

CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday ↗

August 23, 2024

Via Benzinga

Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session ↗

August 15, 2024

Via Benzinga

ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 14, 2024

ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

7 Biotech Stocks to Keep on Your Clinical Radar ↗

July 23, 2024

Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.

Via InvestorPlace

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years ↗

July 10, 2024

FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.